Simrat Randhawa Sells 26,530 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Simrat Randhawa also recently made the following trade(s):

• On Thursday, March 12th, Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $84.97 on Thursday. Dianthus Therapeutics, Inc. has a 52-week low of $16.64 and a 52-week high of $96.50. The firm has a 50 day moving average price of $87.18 and a two-hundred day moving average price of $63.27. The firm has a market cap of $4.65 billion, a price-to-earnings ratio of -20.57 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. As a group, equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently bought and sold shares of the business. Fairmount Funds Management LLC grew its position in Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after purchasing an additional 600,000 shares during the period. Vestal Point Capital LP grew its position in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the period. Wellington Management Group LLP grew its position in Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the period. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the period. Finally, TCG Crossover Management LLC grew its position in Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on DNTH. Wells Fargo & Company began coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price target for the company. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 9th. Oppenheimer raised their price target on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Finally, Wolfe Research initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday, April 9th. They issued an “outperform” rating and a $98.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.